Health ❯ Healthcare ❯ Clinical Trials ❯ Phase 3 Trials

MajesTEC-3 Trial

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

The voucher shortens FDA review to one to two months post‑submission.

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show